Tolerability and User Handling Study of an Autoinjector to Administer 180 microg/0.5 mL Peginterferon alfa-2a (Pegasys, PEG-IFN).
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 15 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Apr 2010 Actual initiation date (1 Mar 2010) added as reported by Roche record.
- 16 Apr 2010 Status changed from not yet recruiting to recruiting as reported by Roche record.